The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423.

Hashimoto H, Sudo T, Maruta H, Nishimura R

Drug Discov Ther. 2010; 4(1):1-4.

Summary Full Text (PDF)

Design, synthesis, and primary activity evaluation of pyrrolidine derivatives as matrix metalloproteinase inhibitors.

Zhang J, Li X, Zhu HW, Wang Q, Feng JH, Mou JJ, Li YG, Fang H, Xu WF

Drug Discov Ther. 2010; 4(1):5-12.

Summary Full Text (PDF)

Hypotensive response in rats and toxicological mechanisms induced by shuanghuanglian, an herbal extract mixture.

Wang HS, Cheng F, Shi YQ, Li ZG, Qin HD, Liu ZP

Drug Discov Ther. 2010; 4(1):13-18.

Summary Full Text (PDF)

In vitro modulating effects of glutathione on vascular tension and involvement of extracellular calcium.

Chaothanaphat N, Dhumma-Upakorn P, Jianmongkol S

Drug Discov Ther. 2010; 4(1):19-25.

Summary Full Text (PDF)

Evaluation of in vitro dissolution profile comparison methods of sustained release tramadol hydrochloride liquisolid compact formulations with marketed sustained release tablets.

Karmarkar AB, Gonjari ID, Hosmani AH, Dhabale PN

Drug Discov Ther. 2010; 4(1):26-32.

Summary Full Text (PDF)

Formulation and evaluation of clotrimazole from pluronic F127 gels.

EL-Houssieny BM, Hamouda HM

Drug Discov Ther. 2010; 4(1):33-43.

Summary Full Text (PDF)

Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers.

Sweeney KR, Gastonguay MR, Benincosa L, Cronenberger CL, Glue P, Malhotra BK

Drug Discov Ther. 2010; 4(1):44-53.

Summary Full Text (PDF)